he aim of treatment for acute myocardial infarction (AMI) is to restore full antegrade blood flow in the infarct-related artery (IRA) and minimize ischemic damage to the myocardium. Thrombolytic therapy is an option, but primary percutaneous coronary intervention (PCI) is the treatment of choice, based on lower rates of recurrent ischemia or infarction and good success rates in restoring antegrade blood flow in the IRA. 1,2 However, primary PCI is associated with a serious problem known as the no-reflow phenomenon (Thrombolysis In Myocardial Infarction (TIMI) flow ≤2), which occurs in 5-25% of cases. 3, 4 Although PCI achieves full patency of epicardial arteries, patients who develop this phenomenon are at increased risk for left ventricular dysfunction, more progressive myocardial damage, and have higher rates of morbidity and mortality. 5, 6 A number of studies have focused on the risk factors, but most of those investigators used nuclear imaging techniques, 7 myocardial contrast echocardiography, 8 Doppler flow measurements, 9 TIMI frame count method 10 or myocardial blush grade 11 to assess no-reflow phenomenon.
multivessel disease; patients with saphenous vein grafts or left internal mammary artery lesions; patients treated with thrombolytic therapy or platelet glycoprotein IIb/IIIa receptor antagonists prior to procedure, and cases where the procedure did not achieve coronary artery patency. In total 382 patients (330 men, aged 19-85 years; mean age, 52.6±11.0 years) constituted the study population and of them 4 (0.9%) were admitted to hospital more than 12 h after onset of AMI and were still exhibiting symptoms at the time of admission.
The patients were divided into 2 groups based on postprocedural TIMI flow in the IRA: TIMI flow ≤2 (no-reflow) and TIMI flow 3 (reflow).
Angiographic Analysis and Primary PCI Procedure
Upon admission, all patients were treated with 300 mg aspirin PO, intravenous nitroglycerin, and at least 10,000 U unfractionated heparin. In all cases, the femoral artery was cannulated with an 8F sheath and coronary artery cannulation was performed using an 8F guiding catheter. Before the primary PCI procedure, standard left and right coronary angiograms with at least 2 best projections were obtained for each individual. Two experienced interventional cardiologists (CK and KS) who were unaware of patients' clinical data carefully assessed a set of parameters for each angiogram and reached consensus on the findings. These parameters were: morphology of the IRA, Rentrop collateral flow, 13 angiographic features of the target lesion, and TIMI flow grades before and after primary PCI. Quantitative angiographic analyses were also carried out to determine reference luminal diameter (RLD), target lesion length and post-procedural minimal luminal diameter (MLD), using a digital edge detection algorithm, 14 and the frames analyzed were end-diastolic frames that demonstrated the stenosis in its most severe form in a non-foreshortened projection. The contrast-filled guiding catheter was used as a calibration standard. Primary PCI was performed using standard technique. Decisions to perform balloon angioplasty or stent implantation were made at the surgeon's discretion during primary PCI. Stent implantation was strongly encouraged unless the IRA was heavily calcified or RLD was <2.5 mm. Bare metal stents were used for all stenting procedures.
For each case, specific angiographic features of the lesion responsible for the infarction were recorded: (1) thrombus burden (mild, moderate or high), (2) type of total occlusion if present (tapered or cut-off lesion), (3) type of lesion if subtotal occlusion is present (eccentric or concentric lesion), (4) length of target lesion (≤13.5 mm or >13.5 mm) and (5) lesion location (proximal, mid or distal lesion). Thrombus burden was evaluated according to the TIMI thrombus classification. 15 It was also classified as mild if consistent with TIMI thrombus class 0 and 1, moderate if consistent with TIMI thrombus class 2 and 3, and high if the greatest linear dimension of the thrombus is more than TIMI thrombus class 3.
Each patient was treated with clopidogrel for at least 2 months after PCI. Infarct size was estimated based on the measurement of peak serum creatine kinase (CK) activity, and peak enzyme release was assessed using 5-6 serial measurements taken within the first 96 h after symptom onset. Evaluation of ST-segment resolution was done before and 1 h after primary PCI, as described previously. 16 Only 243 electrocardiograms (ECGs; 63.6% of the 382 total cases) were completely interpreted. In the remaining cases, ECGs were not assessed because of missing data, inadequate strips, presence of idioventricular rhythm, functioning ventricular pacemaker or new onset left bundle-branch block.
Definitions
AMI was defined as typical chest pain of >30 min duration and either ST segment elevation of >1 mm in 2 consecutive leads or new onset left bundle-branch block with 2-fold elevation of CK and CK-MB fraction. Pre-infarction angina was defined as typical anginal chest pain in the 48-h period preceding the infarction. Reperfusion time was defined as the time from onset of chest pain to first balloon inflation. Multivessel disease was defined as >50% diameter stenosis of 2 or more major epicardial coronary arteries. Good collateral flow was defined as Rentrop collateral flow 2-3. Occlusion was defined as tapered type if the lesion morphology featured a tapered end and as cut-off type if the lesion morphology featured an abrupt end (no tapering). In cases of subtotal obstruction, a lesion was defined as eccentric if its most protruding margin was located in the outer quarter of an apparently normal vessel lumen. On angiography before primary PCI, a thrombus was identified as any intraluminal filling defect near the target lesion that was not associated with calcification. A patient was considered to exhibit no-reflow phenomenon if blood flow in the target vessel was TIMI ≤2 flow despite successful dilatation and absence of mechanical complications such as dissection, spasm or angiographically evident distal embolization after completion of the procedure.
Statistical Analysis
Data are expressed as mean ± SD. Continuous variables were compared using the unpaired Student's t-test. Chisquare analysis was used to test differences between proportions. Fisher's exact test was used when the expected value for a cell was <5. Receiver-operating characteristic (ROC) curve analysis was done to determine the best cut-off value for target lesion length that predicted no-reflow phenomenon. For 13.5-mm lesion length, 78% sensitivity and 62% specificity was found on ROC curve analysis. Multiple stepwise logistic regression analysis was used to identify independent predictors of no-reflow phenomenon. Patients age (>60 years), reperfusion times, thrombus burden, target lesion length (>13.5 mm), RLD and reperfusion method were included in the analysis. All statistical analysis were done using SPSS version 11.0 (SPSS Inc, Chicago, IL, USA). Statistical significance was defined as p<0.05.
Results

Patient Characteristics
Of the 382 patients who underwent primary PCI on an IRA, 93 (24.3%) developed no-reflow phenomenon after the procedure. Table 1 shows a comparison of the baseline 
Angiographic Findings and Primary PCI Procedure
Analysis of the angiographic data revealed that noreflow was significantly more frequent in patients who had low (≤1) initial TIMI flow (93.3% vs 69.9%, respectively), cut-off type total occlusion (43% vs 28.4%, respectively), long target lesion (>13.5 mm, 59.1% vs 32.9%, respectively) and large vessel diameter (3.3±0.4 vs 3.1±0.3, respectively) ( Table 2) . It was also observed that the no-reflow group mainly consisted of patients with delayed reperfusion (≥4 h) and high thrombus burden (58.1% vs 43.6%, respectively) (Fig 1) . However, the presence of multivessel disease, IRA, target lesion locations, lesion types in subtotal occlusions and collateral flow grades showed no difference between the 2 groups (p>0.05 for all).
Among the procedural features, the incidence of noreflow was significantly lower in the direct stenting group than in the group with stenting with predilation or with balloon angioplasty (9/96 (8.6%), 77/183 (29.6%), 7/10 (41.2%) respectively, p<0.001). The number of implanted stents, maximal inflation pressures and repeated balloon dilatations did not affect the incidence of no-reflow (p>0.05 for all). However, the mean implanted stent length was significantly greater in the no-reflow group (22.6±7.2 vs 19.2± 6.2 mm for no-reflow and reflow, respectively; p<0.01).
Independent Predictors of No-Reflow Phenomenon
Multiple stepwise logistic regression analysis identified that advanced age (>60 years, odds ratio (OR) 1.04, 95% confidence interval (CI) 1.01-1.06; p=0.001), delayed reperfusion (≥4 h, OR 1.4, 95% CI 1.19-1.69; p<0.001), low (≤1) TIMI flow prior to PCI (OR 1.1, 95% CI 1.08-1.25; p<0.001), target lesion length (>13.5 mm, OR 5.1, 95% CI 2.09-12.6; p<0.001) and high thrombus burden (OR 1.6, 95% CI 1.02-2.82; p=0.03) were independent predictors of no-reflow phenomenon (Table 3) .
Discussion
In our study, the rate of no-reflow phenomenon after primary PCI was 24.3%, which was consistent with previously published no-reflow rates of 5-25% of. 3, 4 Certain factors, such as advanced age, delayed reperfusion, low TIMI flow prior to PCI, long target lesion and high thrombus burden, were found to be independent predictors of this peculiar phenomenon.
Large-scale prospective studies performed on elderly patients with AMI indicate that in-hospital and long-term mortality rates are higher and the success rate of primary PCI is lower than for younger patients, 17, 18 mainly because of delayed hospital admission of the elderly and their increased number of co-morbidities. Certain conditions, such as diffuse coronary atherosclerosis, severe vascular calcification, predisposition to distal microembolization and disrupted microcirculation, are more common in elderly patients. These pathologic changes are related to advanced age and probably cause a tendency to distal embolization during primary PCI, consequently resulting in the no-reflow phenomenon.
In our study, patients who had low (≤1) TIMI flow in the IRA prior to PCI showed a 1.1-fold higher rate of no-reflow phenomenon than patients with good (≥2) TIMI flow on baseline angiography. In a large cohort of patients with AMI, Brodie et al indicated that procedural success was better in patients with initial TIMI 2-3 flow (97.4% for TIMI 2 vs 93.8% for TIMI 3 flow, respectively; p=0.02), and catheterization laboratory events were less frequent. 19 More recently, De Luca et al showed that pre-procedural good TIMI flow was strongly related to post-procedural TIMI 3 flow, myocardial blush grade 2-3 and lower enzymatic infarct size. 20 Good patency of the IRA prior to PCI suggests lower thrombus burden, spontaneous endogenous lysis of the thrombus, resolution of vasospasm and smaller infarct size. Thus, treatment of AMI should focus on achieving sustained antegrade blood flow as soon as possible. Although primary PCI is superior to thrombolytic therapy in achieving TIMI 3 flow, its main limitation is the time delay while transferring patients to tertiary PCI centers. Administration of platelet glycoprotein IIb/IIIa receptor antagonists or lowdose thrombolytic drugs in the early phase of AMI, when a delay to primary PCI is expected, can help restore early IRA patency and increase the chances of achieving post-procedural TIMI 3 flow. 21, 22 One of the most important issues related to no-reflow phenomenon is the reperfusion time. In our study, patients with long reperfusion time (≥4 h) had a significantly greater thrombus burden and a 1.4-fold increase in no-reflow rates than patients with short reperfusion times. It is well established that prolonged ischemia leads to edema of distal capillary beds, swelling of myocardial cells, neutrophil plugging and alterations of capillary integrity. 23, 24 Furthermore, delayed reperfusion can result in an older, more organized intracoronary thrombus, 25 which may increase the risk of distal embolization during primary PCI and reduce the likelihood of achieving TIMI 3 flow after the procedure. Although Yip et al did not detect a direct relationship between thrombus burden and reperfusion time, they demonstrated that among patients with high thrombus burden, the rate of no-reflow phenomenon was lower in the subgroup with reperfusion time <4 h. 26 In the early stages of AMI, the thrombus is rich in thrombocytes and relatively easier to lyse with adjunctive pharmacotherapy. With a longer time to reperfusion, the thrombus takes on more and more erythrocytes and becomes more firm. Such thrombi tend to fragment with balloon dilatation, which can lead to distal embolization and could explain why the no-reflow phenomenon occurs less frequently in cases of early reperfusion. As shown previously, in cases of long reperfusion time and high thrombus burden, the use of a distal protection device may improve myocardial reperfusion by alleviating the adverse effects of the organized thrombus. 27 However, the no-reflow phenomenon can occur even in patients with AMI who have a low thrombus burden and long reperfusion time. Even if the material potential to embolize is small, prolonged ischemia can disrupt the microvascular bed 28 and the degree of this disruption is known to be a key factor in the pathogenesis of no-reflow. Delayed reperfusion leads to greater destruction of the microvasculature, which is why an increased rate of no-reflow is seen in cases of prolonged reperfusion.
It is well known that acute coronary syndromes almost always result from plaque rupture or fissuring with superimposed thrombus formation. Microvascular embolization of plaque material and thrombus content can occur spontaneously or iatrogenically during the PCI procedure. 29 Watanabe et al investigated pre-interventional intravascular ultrasound (IVUS) findings and their results suggest a possible relationship between lipid-rich plaque and the noreflow phenomenon. 30 Also, Tanaka et al used IVUS to examine plaque burden and identified higher lipid content in the plaque inner core and width of the external elastic membrane as independent markers for no-reflow phenomenon. 31 Those studies indicate that not only thrombus burden but also plaque material determines the development of noreflow phenomenon. It is reasonable to equate lesion length with plaque burden. In our study, we found that patients with a target lesion length >13.5 mm were 5.4-fold more likely to develop the no-reflow phenomenon than those with a target lesion length ≤13.5 mm. As suggested by Isaaz et al, 32 we advise treatment with low-dose thrombolytic drugs or glycoprotein receptor antagonists and postponing of PCI if adequate antegrade flow is achieved by initial predilatation in patients with high thrombus burden or a long target lesion.
In order to reduce the risk of no-reflow developing during primary PCI, we make every effort to avoid or minimize trauma to the vessel wall. Specifically, it is important to avoid repetitive balloon dilatations and use the shortest stent at 1 tray if possible. In our experience, we have often achieved TIMI 3 flow in the IRA after predilation, yet the same patient developed no-reflow phenomenon following stent implantation. In recent years, it has been shown that coronary stent implantation without predilation is feasible and can be performed safely in selected patients with AMI. 33 Nevertheless, for direct stenting, a certain level of basal antegrade TIMI flow and suitable lesion features (ie, subtotal occlusion without angulation or severe calcification) are required. Several mechanisms may explain the reduced no-reflow rates in direct stenting. The lack of predilation before stenting may decrease the likelihood of thrombus and/or plaque content dislodgement and subsequent distal embolization. The complete and direct scaffolding of a mural thrombus at 1 tray may be another explanation of the preventive effect of direct stenting. However, the presence of basal TIMI flow and/or easily accessible lesion features in the IRA before the procedure is itself an independent predictor of increased success rate. Thus the fact that direct stenting can decrease no-reflow remains a questionable issue.
Study Limitations
First, we did not use IVUS to quantitatively evaluate thrombus burden and plaque content. However, IVUS can prolong a PCI procedure and is more expensive than conventional primary PCI. Second, we excluded patients who received pre-procedural glycoprotein IIb/IIIa receptor antagonists, the use of which would have reduced the incidence of no-reflow. Third, we did not perform in-depth analysis of factors that may prevent no-reflow phenomenon, such as cigarette smoking or direct stenting. Moreover, we did not evaluate microvascular no-reflow using myocardial contrast echocardiography or nuclear scintigraphy.
In conclusion, the pathogenesis of no-reflow phenomenon is complex and multifactorial. In the light of our recent study, patients who are likely to develop the no-reflow phenomenon after primary PCI can be predicted by simple clinical and angiographic features. In particular, patients with advanced age, delayed reperfusion, low TIMI flow and/or high thrombus burden on baseline angiography and patients who have a long target lesion are at increased risk for no-reflow development. In this selected group of patients, the use of a distal protection device or administration of pharmacologic agents that have favorable effects on microvasculature (ie, platelet glycoprotein IIb/IIIa antagonists, low-dose thrombolytics) may be of value. Because most patients with AMI have a combination of these factors, combined treatment strategies are preferred.
